Trial · NCT00118248

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

NCT00118248, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2014-05-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer. Trials, record NCT00118248. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00118248

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
NCT number: NCT00118248
Status: Completed
Phases: Phase 2
Enrollment: 41 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
Interventions: tanespimycin
First posted: 2005-07-11
Last updated: 2017-02-15
Results first posted: 2014-05-06

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin)	1 year	The one-year treatment failure free rate is 100% times the proportion of eligible patients who remain on treatment and are progression-free at least one year after treatment start. A 90% confidence interval for the one year treatment failure free rate was constructed using the properties of the binomial confidence interval. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Patients that are not classified as having a progression are termed progression-free.
Secondary	Overall Response	Baseline, every 3 courses, and at the end of treatment study	The number of responses were categorized and summarized independently within each of the patient groups. Participants were evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.0. Complete Response (CR): Disappearance of all lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest dimension (LD) of target lesions taking as reference the baseline sum LD.
Secondary	Progression-Free Survival	Every 3 months for up to 3 years	Defined as the time from registration to the date of progression or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Patients that are not classified as having a progression are termed progression-free. Estimated using the Kaplan-Meier method.
Secondary	Overall Survival	Every 3 months until progression, and then every 6 months up to 3 years	Defined as the time from registration to date of last follow-up or death due to any cause. Estimated using the Kaplan-Meier method.
Secondary	Toxicity	Every 3 courses during treatment (median cycle number was 5 with a maximum of 38 cycles)	Defined as the number of participants reporting grade 3 or higher adverse events that are classified as either possibly, probably, or definitely related to study treatment. Determined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin)	1 year	All patients were evaluable for this endpoint in this group.	percentage of participants	NUMBER
SECONDARY	Overall Response	Baseline, every 3 courses, and at the end of treatment study	All participants were evaluated for response.	participants	NUMBER
SECONDARY	Progression-Free Survival	Every 3 months for up to 3 years	All participants were evaluable for this endpoint.	months	MEDIAN
SECONDARY	Overall Survival	Every 3 months until progression, and then every 6 months up to 3 years	All patients were evaluable for this endpoint.	years	MEDIAN
SECONDARY	Toxicity	Every 3 courses during treatment (median cycle number was 5 with a maximum of 38 cycles)	All participants were evaluable for this endpoint.	participants	NUMBER

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin)	Advanced Medullary Thyroid Carcinoma Group		5.9	90% Confidence Interval 0.3 to 25.0	percentage of participants
Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin)	Differentiated Thyroid Carcinoma		12.5	90% Confidence Interval 3.5 to 29.2	percentage of participants
Overall Response	Advanced Medullary Thyroid Carcinoma Group	Complete Response (CR)	0		participants
Overall Response	Differentiated Thyroid Carcinoma	Complete Response (CR)	0		participants
Overall Response	Advanced Medullary Thyroid Carcinoma Group	Partial Response (PR)	1		participants
Overall Response	Differentiated Thyroid Carcinoma	Partial Response (PR)	0		participants
Progression-Free Survival	Advanced Medullary Thyroid Carcinoma Group		6.4	95% Confidence Interval 2.7 to 17.2	months
Progression-Free Survival	Differentiated Thyroid Carcinoma		4.1	95% Confidence Interval 2.2 to 8.7	months
Overall Survival	Advanced Medullary Thyroid Carcinoma Group		2.1	95% Confidence Interval 0.67 to 3.1	years
Overall Survival	Differentiated Thyroid Carcinoma		1.5	95% Confidence Interval 0.73 to 3.5	years

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Advanced Medullary Thyroid Carcinoma Group	17
Overall Study	STARTED	Differentiated Thyroid Carcinoma	24
Overall Study	COMPLETED	Advanced Medullary Thyroid Carcinoma Group	17
Overall Study	COMPLETED	Differentiated Thyroid Carcinoma	24
Overall Study	NOT COMPLETED	Advanced Medullary Thyroid Carcinoma Group	0
Overall Study	NOT COMPLETED	Differentiated Thyroid Carcinoma	0

Source ClinicalTrials.gov

Adverse events120

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hemoglobin decreased	Blood and lymphatic system disorders	All Patients	24	41	104
other	Lymph node pain	Blood and lymphatic system disorders	All Patients	2	41	3
other	Cardiac disorder	Cardiac disorders	All Patients	1	41	1
other	Ear disorder	Ear and labyrinth disorders	All Patients	1	41	1
other	Ear pain	Ear and labyrinth disorders	All Patients	1	41	1
other	Hearing impaired	Ear and labyrinth disorders	All Patients	1	41	11
other	Tinnitus	Ear and labyrinth disorders	All Patients	1	41	12
other	Hypothyroidism	Endocrine disorders	All Patients	1	41	4
other	Photophobia	Eye disorders	All Patients	1	41	1
other	Constipation	Gastrointestinal disorders	All Patients	2	41	13

1 to 10 of 120Source ClinicalTrials.gov

See all 120 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	All Patients
Total, other adverse events	All Patients	39	41
Total, serious adverse events	All Patients	13	41

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA015083	Mayo Clinic Comprehensive Cancer Center Support Grant	WILLMAN, CHERYL LYNN	MAYO CLINIC ROCHESTER	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00118248

GET https://conductscience.org/api/trials/v1/NCT00118248/events?page=2

API reference For AI assistants